8-K: Lifecore Biomedical Announces Business Update, Provides Fiscal 2024 Guidance and Capacity Expansion Progress

Lifecore Biomedical provided a business update, including preliminary financial data, full-year fiscal 2024 guidance, and progress on its development portfolio and capacity expansion.

Summary

• Lifecore Biomedical, a contract development and manufacturing organization (CDMO), has released a business update including preliminary financial results for the fiscal quarters ended August 27, 2023, November 26, 2023, and February 24, 2024, and the nine months ended February 24, 2024.
• The company's year-to-date results are consistent with prior expectations, with an anticipated lift in the second half of the fiscal year.
• Lifecore is experiencing commercial momentum within its development portfolio and is progressing with capacity expansion projects.
• The company expects its theoretical annual aseptic production capacity to increase to approximately 70 million units by fiscal year 2027, more than tripling its current capacity of 22 million units.
• Lifecore's 5-head filler is expected to be GMP ready in August 2024.
• The company has increased its Hyaluronic Acid (HA) capacity by 38% since the beginning of fiscal year 2024 and anticipates further increases through yield improvements of approximately 20% during fiscal year 2025.
• Lifecore's fiscal 2024 revenue is expected to be between $125 million and $130 million, and adjusted EBITDA is expected to be between $13.5 million and $16.9 million.
• Capital expenditures for fiscal year 2024 are expected to be between $19 million and $20 million, excluding capitalized interest.
• The company's development portfolio includes 33 projects, with a doubling of prospective engagements with larger pharmaceutical companies.
• Lifecore has 68 additional opportunities in its prospective pipeline currently in discussion.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth potential, capacity expansion, and a robust pipeline. However, the preliminary nature of the financial results and the presence of significant debt and liabilities temper the overall sentiment.

Positives

• Lifecore's year-to-date performance is in line with expectations, indicating a stable business trajectory.
• The company is experiencing a lift in the second half of the fiscal year, suggesting positive momentum.
• The planned capacity expansion to 70 million units by fiscal year 2027 represents a significant growth opportunity.
• The 38% increase in HA capacity since the beginning of fiscal year 2024, with a further 20% increase expected in fiscal year 2025, demonstrates strong operational improvements.
• The doubling of prospective engagements with larger pharmaceutical companies indicates a growing market presence.
• The company has a strong pipeline of 68 additional opportunities in discussion.
• The company has successfully entered into an amended and restated supply agreement with one of its customers which provided revised pricing and payment of a $5 million working capital deposit.
• The company has made significant progress in clearing up former business dealings associated with its since divested Curation Foods segment, including $2.7 million of cash proceeds from its sale of O Olive, receipt of a $1.85 million insurance settlement, and $0.9 million in settlement of a note receivable from a former supplier.

Negatives

• The preliminary financial results are subject to change pending the completion of quarterly financial closing procedures and audit adjustments.
• The company's actual financial results may differ materially from the preliminary estimates.
• The company has a significant amount of debt, with total debt at $121.5 million and net debt at $118.3 million as of February 24, 2024.
• The company has a debt derivative liability of $60.2 million as of February 24, 2024.
• The company has a Series A convertible preferred stock liability of $41.7 million as of February 24, 2024.

Risks

• The company's actual financial results may differ materially from preliminary estimates due to audit adjustments and other developments.
• The company's ability to successfully enact its business strategies, including capacity generation and attracting demand for its services, is subject to risk.
• The company's ability to become current with its reports with the Securities and Exchange Commission (the SEC) and regain compliance with applicable listing standards under Nasdaq is not guaranteed.
• The company faces risks related to competition, inflation, changes in market cycles, and general economic conditions.
• The company's access to capital and its ability to expand its relationships with existing customers or attract new customers are subject to risk.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Lifecore anticipates continued growth in its CDMO business, driven by capacity expansion, a strong development pipeline, and increasing demand for its services. The company expects to triple its manufacturing capacity by fiscal year 2027 and is focused on bringing new projects online and converting existing commercial opportunities.

Management Comments

• James G. Hall, President and Chief Executive Officer of Lifecore, stated that the business update is consistent with expectations laid out last August.
• Mr. Hall noted that the team has been ramping up commercial presence in the market over the past two years in advance of expanded capacity.
• Mr. Hall mentioned that recent industry disruptions have created a heightened desire for quality filling capacity.
• Mr. Hall stated that Lifecore has a lengthy runway of growth ahead with approximately 70 million units of theoretical capacity when new fillers are installed, tested, and qualified.
• Mr. Hall noted that the company has the potential to triple its current manufacturing capacity and revenue generating capacity from anticipated fiscal year 2024 levels.

Industry Context

Lifecore's update comes at a time when the CDMO market is experiencing increased demand due to industry disruptions and a growing trend of outsourcing injectable manufacturing. The company's focus on quality and capacity expansion positions it well to capitalize on these trends. The company is also seeing increased interest from larger pharmaceutical companies, which is a positive sign for its future growth.

Comparison to Industry Standards

• Lifecore's planned capacity expansion to 70 million units by FY27 is a significant increase, positioning them to compete with larger CDMOs like Catalent and Lonza, who have large-scale manufacturing capabilities.
• The company's focus on high-quality, sterile injectable products aligns with the industry's increasing demand for complex biologics manufacturing, similar to companies like Samsung Biologics and WuXi Biologics.
• Lifecore's 38% increase in HA capacity since the beginning of fiscal year 2024, with a further 20% increase expected in fiscal year 2025, demonstrates a strong commitment to operational improvements, which is a key differentiator in the competitive CDMO landscape.
• The company's development portfolio of 33 projects and 68 additional opportunities in discussion indicates a robust pipeline, which is comparable to other CDMOs that focus on early-stage development and clinical trial manufacturing.
• The company's focus on both HA and non-HA based CDMO services provides a diversified revenue stream, which is a strategy employed by many successful CDMOs to mitigate risk and capitalize on different market segments.

Management Changes

Stakeholder Impact

• Shareholders can expect potential long-term growth and increased revenue from capacity expansion and a strong development pipeline.
• Employees may see increased job opportunities and growth potential as the company expands its operations.
• Customers can expect improved capacity and quality of services as Lifecore continues to invest in its facilities and capabilities.
• Suppliers may see increased demand for their products as Lifecore's production capacity grows.
• Creditors may see increased stability and reduced risk as the company's financial performance improves.

Next Steps

• Lifecore will continue to work towards the installation and qualification of its high-speed multi-purpose 5-head and 10-head isolator fillers.
• The company will continue to advance its development portfolio and seek new commercial opportunities.
• Lifecore will focus on increasing its HA capacity and improving yields.
• The company will file its Quarterly Reports on Form 10-Q for the Historical Periods.
• The company will continue to invest in people and systems to support its expanded development pipeline and services.

Key Dates

Keywords

CDMO, contract manufacturing, Hyaluronic Acid, pharmaceutical, biotechnology, aseptic filling, capacity expansion, development portfolio, EBITDA, GMP, injectables